Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Antivirals—an increasingly healthy investment

Continued investment from big pharma and a slew of new drugs with novel mechanisms of action are fueling investor interest in the antiviral space.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The antiviral market.

References

  1. Anonymous. The World Market for Anti-Infectives, Volume III. Antiviral Drugs (Kalorama Information, Rockville, MD, USA, 2007).

  2. Anonymous. The Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape (Arrowhead Publishers, Minneapolis, MN, USA, 2007).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author is an employee of Novartis Vaccines

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCarthy, B. Antivirals—an increasingly healthy investment. Nat Biotechnol 25, 1390–1393 (2007). https://doi.org/10.1038/nbt1207-1390

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1207-1390

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing